Skip to main content
Premium Trial:

Request an Annual Quote

OGT Shutters Nonessential Tridend Unit as It Bets on New Arrays, Markets

BOSTON (GenomeWeb News) — Oxford Gene Technology has closed one of its business units as it concentrates on developing and launching new microarray products and growing its licensing revenue in newer markets like Japan, according to a company official.
OGT's CEO Mike Evans said this week that OGT had decided to close down the unit, called Tridend, because it "didn't fit with OGT's core strategy." Evans spoke with GenomeWeb News at IBC Life Sciences' Discovery 2 Diagnostics conference, held here this week.
Evans said that OGT will now "look at ways of utilizing the Tridend technology externally" with partners and is considering licensing opportunities for the IP behind Tridend.
Evans told GenomeWeb News sister publication BioArray News in May 2005 that Tridend is focused on commercializing the firm's mass spectrometry technology for applications such as genotyping or protein characterization. The unit was one in development as the company sought to expand its business beyond licensing.
In recent months, however, OGT has been more focused on launching a series of prokaryotic chromatin immunoprecipitation (ChIP)-on-chip arrays as well as chips for comparative genomic hybridization.
The firm also signed four licensing deals in Japan in August, and signed another licensing deal with Invitrogen last week.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.